|
|
U.S. Anti-obesity Prescription MarketsPublished by: Frost & Sullivan Published: Sep. 26, 2006 - 115 Pages Table of Contents
1. Executive Summary 1. Introduction 2. Introduction to U.S. Anti-obesity Prescription Markets 1. Introduction 1. Market Overview 2. Research Scope and Methodology 2. Basic Obesity Terminologies and Definitions 1. Obesity Definition 2. Obesity Classification 3. Obesity Etiology 4. Obesity Diagnosis 3. Market Dynamics 1. Market Engineering Analysis 2. Market Drivers a. Rapidly Growing Prevalence of Overweight and Obese Population Increases Market Potential b. New Improved Products Fuel Patient Demand c. Evidence of Significant Health Benefits Derived from Modest Weight Loss Coupled with Growing Obesity-related Healthcare Costs Stimulates Healthcare Provider Coverage of Pharmacotherapy d. Combination Therapy Decreases Competition and Increases Efficacy and Revenue Potential 3. Market Restraints a. Changing Clinical Trial Landscape Impedes Market Success b. Modest Efficacy of Pharmacotherapy Deters Market Demand c. High Cost Constrains Patient Medication Use 4. Market Trends 4. Industry Challenges and Strategic Recommendations 1. Industry Challenges 2. Strategic Recommendations 5. Frost & Sullivan Awards 1. Industry Innovation and Advancement of the Year 2. Technology Innovation of the Year Award 3. Product Differentiation Innovation of the Year Award 3. Market Segmentation 1. Disease and Treatment Overview 1. Obesity Prevalence Forecasts 2. Obesity Diagnosed and Treated Patient Forecasts 3. Obesity Patient Compliance 4. Obesity Comorbid Conditions 5. Unmet Needs in Obesity 2. Product Analysis 1. Overview of Marketed Products 2. Xenical and Meridia SWOT Analyses 3. Key Patent Expirations 3. Competitive and Pipeline Analysis 1. Competitive Landscape 2. Competitor Profiles 3. Pipeline Analysis 4. Anticipated Launch Dates 5. Alliances Acquisitions and Licensing Agreements 4. Market Forecasts 1. Revenue Forecasts and Assumptions 2. Pricing Trends 3. Market Share Analysis 4. Appendix 1. Decision Support Databases 1. Total Population 2. Prevalence of Diabetes Mellitus 3. Diabetes Incidence 4. Prevalence of Obesity 5. Mortality Due to Coronary Heart Disease List of Figures Chapter 2 Chapter 3 AbstractResearch OverviewThe Frost & Sullivan research service entitled U.S. Anti-Obesity Prescription Markets provides analysis of treated patients, market revenues, and pipeline products for the obese market. In this research service, Frost & Sullivan's expert analysts thoroughly examine emerging appetite suppressants, digestion modifiers, energy expenditure modifiers, and combination therapy approaches. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: By Application:
Rapidly Growing Obese Population Increases Market Potential With a prevalent population of 68.3 million adults in 2005, obesity has come to represent a serious healthcare epidemic in the United States. The recognition that around 80 percent of type II diabetes cases can be treated through weight loss has clearly positioned obesity as a major cause of disease, thus elevating the need to produce effective therapeutic approaches to treat this condition. This is likely to propel a treatment practice shift to long-term obesity management, whereby physicians are expected to increasingly prescribe medication as a preventative measure. Further, considering that the growth in obese patient base in being fuelled by an increase in the prevalence of patients classified as overweight, Food and Drug Administration (FDA) guidance may permit the evaluation and labeling of potential weight loss agents in the overweight population with body mass index (BMI) between 25 kg/m2 and 27 kg/m2 as per the recommendations of the American Medical Association, North American association for the study of obesity (NAASO), and the National heart, lung, and blood institute (NHLBI). Despite these growth factors, the changing clinical trial landscape is likely to be a key restraint for market participants. The FDA is currently evaluating recent scientific and medical information and drug development initiatives in obesity to develop an amended obesity guidance document. This new guidance is expected to profoundly impact the success of current drugs in development, and could result in more stringent criteria, such as requirements for long-term safety studies, a clinical trial comparator arm beyond placebo, and greater weight-loss efficacy for market approval. "This apart, the modest efficacy of present day pharmacotherapy is also likely to deter demand," notes the analyst of this research service. "While Fen-phen has had the greatest weight loss efficacy, key components fenfluramine and dexfenfluramine have been withdrawn from market as a result of adverse cardiac effects." Product Improvements likely to Fuel Demand Despite the recent failure of a few anti-obesity drugs due to their side effects and inability to satisfy patient expectations, upcoming therapies are expected to revive demand for anti-obesity medication. Less than 5 percent of the obese population received pharmacotherapy in 2005, indicating a pent up demand for such products. Presently, Sanofi-Aventis’ Accomplia (rimonabant) is receiving tremendous publicity and it is expected that once launched, patients will revisit their physicians to request for a prescription of this new anti-obesity drug. Many other companies are waiting to profit from the success of Accomplia and a rich pipeline of 27 therapeutic candidates promise to heighten demand for obesity treatment in a market with considerable theoretical demand. "With highly anticipated product launches, growing reimbursement of anti-obesity pharmacotherapy and a virtually untapped prevalent population close to 70 million, anti-obesity drug manufacturers are expected to see a sharp increase in market revenues in the near future," says the analyst. "Future growth in the U.S. anti-obesity prescription market is likely to depend a great deal on the availability of safe effective medication and adoption of an obesity disease management strategy by healthcare providers with prevention as a key element." Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||